Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.62 |
| ▸ | MMP9 | P14780 | 1/20 | 0.56 |
| ▸ | MMP8 | P22894 | 1/20 | 0.56 |
| ▸ | MMP14 | P50281 | 1/20 | 0.56 |
| ▸ | MME | P08473 | 5/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | ACE | P12821 | 1/20 | 0.50 |
| ▸ | CPA1 | P15085 | 1/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.50 |
| ▸ | APAF1 | O14727 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12637371 | 1.00 | SIGMAR1 (0.62) | SIGMAR1MMP9MMP8MMP14MME | |
| SCHEMBL1878623 | 1.00 | SIGMAR1 (0.62) | SIGMAR1MMP9MMP8MMP14MME | |
| SCHEMBL8197333 | 1.00 | SIGMAR1 (0.62) | SIGMAR1MMP9MMP8MMP14MME | |
| SCHEMBL12637374 | 1.00 | SIGMAR1 (0.62) | SIGMAR1MMP9MMP8MMP14MME | |
| SCHEMBL16017459 | 0.91 | MMP9 (0.60) | SIGMAR1MMP9MMP8MMEACE | |
| SCHEMBL11015010 | 0.86 | ALDH1A1 (0.58) | SIGMAR1MMP9MMP8MMP14L3MBTL1 | |
| SCHEMBL15592756 | 0.84 | MME (0.58) | MMEACECPA1ACE2L3MBTL1 | |
| SCHEMBL2781126 | 0.84 | MME (0.58) | MMEACECPA1ACE2L3MBTL1 | |
| SCHEMBL123574 | 0.84 | MME (0.58) | MMEACECPA1ACE2L3MBTL1 | |
| SCHEMBL9068541 | 0.84 | MME (0.70) | MMP9MMEACECPA1ACE2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2050738-B1 | NOVEL IMIDAZOLIDINONE DERIVATIVE, METHOD OF PRODUCING THE SAME AND METHOD OF PRODUCING OPTICALLY ACTIVE AMINO ACID | KANEKA CORP (JP) | 2013-07-10 | — | — | EP | disclosed |
| US-7947722-B2 | Imidazolidinone derivative, method of producing the same and method of producing optically active amino acid | KANEKA CORPORATION (JP) | 2011-05-24 | — | — | US | disclosed |
| US-20090209768-A1 | NOVEL IMIDAZOLIDINONE DERIVATIVE, METHOD OF PRODUCING THE SAME AND METHOD OF PRODUCING OPTICALLY ACTIVE AMINO ACID | KANEKA CORPORATION (JP) | 2009-08-20 | — | — | US | disclosed |
| EP-2050738-A1 | NOVEL IMIDAZOLIDINONE DERIVATIVE, METHOD OF PRODUCING THE SAME AND METHOD OF PRODUCING OPTICALLY ACTIVE AMINO ACID | Kaneka Corporation (JP) | 2009-04-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209768-A1 | NOVEL IMIDAZOLIDINONE DERIVATIVE, METHOD OF PRODUCING THE SAME AND METHOD OF PRODUCING OPTICALLY ACTIVE AMINO ACID | DAO, RCC2, AADAT | SIGMAR1 3218/4885MMP9 2902/4885MMP8 2605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.